Olivia Ball, MD
Radiation Oncology · Mobile, ALNPI 1366887945
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $570 and has fallen 73.7% since, to $150 in 2025.
Across 122 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$377
- AstraZeneca$174
- Merck$127
- Amgen$123
- Daiichi Sankyo Inc.$103
- Incyte Corporation$103
- plus $1K from 36 others
What the payments were for
- Food & beverage$2,165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $377 |
| AstraZeneca(2 entities) | 9 | $174 |
| Merck | 7 | $127 |
| Amgen | 7 | $123 |
| Daiichi Sankyo Inc. | 6 | $103 |
| Incyte Corporation | 6 | $103 |
| Genentech USA, Inc. | 4 | $78 |
| Lilly USA, LLC | 5 | $76 |
| Johnson & Johnson | 4 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Eisai Inc. | 3 | $56 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Bayer | 3 | $50 |
| Bioprotect Medical, Inc. | 1 | $43 |
| Teleflex LLC | 2 | $43 |
| Verastem, Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Seagen Inc. | 2 | $35 |
| ADC Therapeutics America, Inc. | 2 | $35 |
| Pfizer | 2 | $33 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Sanofi | 2 | $32 |
| Morphosys, US Inc. | 2 | $32 |
| Novocure Inc. | 1 | $29 |
| Exelixis Inc. | 2 | $28 |
| Puma Biotechnology, Inc. | 2 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Genmab U.S., Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $18 |
| Secura Bio, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Sandoz | 1 | $14 |
| Sobi, Inc | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Myriad Genetic Laboratories, Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Veracyte, Inc. | 1 | $11 |
How this compares
$2,165 in reported general payments places this provider in the 65th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pentoxifylline | 11 | $377 |
| Dexamethasone | 11 | $198 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Mobile
- Frank PitruzzelloMobile$6K
- Joseph JonesMobile$5K
- James GalleMobile$4K
- John RussellMobile$2K
- Adam HuddlestonMobile$766
- John RovedaMobile$713
- Robert GilbertMobile$458
- Alexander WhitleyMontgomery$441K
- Drexell BoggsBirmingham$35K
- Christopher JahrausAlabaster$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.